Overview

At a Glance

  • Late-stage therapeutics development company
    • Three principal development programs; 2 designated “breakthrough”*
      • CD34+ cells for ischemic repair (CLBS12*, CLBS14-CMD, CLBS14-NORDA*)
  •  CD34+ cell therapy technology platform includes nearer-term commercial opportunities
    • CLBS12 is an ongoing critical limb ischemia study in Japan with SAKIGAKE designation for expedited review and eligible for early conditional approval
    • CLBS14-CMD is an ongoing proof-of-concept Phase 2 study in the USA for coronary microvascular dysfunction and is supported by a grant from the NIH
    • CLBS14-NORDA is in Phase 3 development in the USA for no option refractory disabling angina
  • Financially stable and debt-free
    • Strong balance sheet (~$43 million cash as of Dec. 31, 2018)
    • Low operating cash burn (~$20 million for year ended Dec. 31, 2018; Cash runway through May 2020)
Sign up to our e-mail list to receive Caladrius announcements.

Stock Chart

Maximum 30 minute delay for quote.

Investor & Media Contact:


Caladrius Biosciences, Inc.

John D. Menditto
Vice President
Investor Relations & Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com